Cargando…

Correction: Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157334/ https://www.ncbi.nlm.nih.gov/pubmed/35640932 http://dx.doi.org/10.1136/jitc-2022-004699corr1

Ejemplares similares

Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
por: Nguyen, Lee S, et al.
Publicado: (2022)

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor-Associated Myocarditis With Persistent Troponin Elevation Despite Abatacept and Prolonged Immunosuppression
por: Liu, Shiying, et al.
Publicado: (2020)

Mode-of-action of the PROPELLA concept in fulminant myocarditis
por: Spillmann, Frank, et al.
Publicado: (2019)

New concepts in fulminant myocarditis and risk of cardiac mortality
por: Ammirati, Enrico, et al.
Publicado: (2017)

Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration
por: Liu, Zhijie, et al.
Publicado: (2022)

Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature
por: Wang, Feifei, et al.
Publicado: (2021)

Delayed Diagnosis and Recovery of Fulminant Immune Checkpoint Inhibitor-Associated Myocarditis on VA-ECMO Support
por: Ramayya, Tarun, et al.
Publicado: (2022)

Early characteristics of fulminant myocarditis vs non-fulminant myocarditis: A meta-analysis
por: Wang, Zicheng, et al.
Publicado: (2019)

A Case of Reversible Very Low Voltage Electrocardiogram in Fulminant Myocarditis
por: Lee, Jong Min, et al.
Publicado: (2013)

Correction: (68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
Publicado: (2022)

A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil
por: Jespersen, Mette Syberg, et al.
Publicado: (2021)

Fulminant myocarditis in the time of coronavirus
por: Cuomo, Vittoria, et al.
Publicado: (2020)

Fulminant myocarditis and COVID-19
por: Joob, Beuy, et al.
Publicado: (2020)

COVID-Induced Fulminant Myocarditis
por: Rodriguez Guerra, Miguel A, et al.
Publicado: (2022)

Correction: Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis
Publicado: (2021)

Correction to: Diagnostic Value of the International Society of Cardio‐Oncology Definition for Suspected Immune Checkpoint Inhibitor–Associated Myocarditis
Publicado: (2023)

Mechanical Unloading by Fulminant Myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA Concepts
por: Tschöpe, Carsten, et al.
Publicado: (2018)

Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy
por: Barham, Whitney, et al.
Publicado: (2021)

Transient Myocarditis Associated with Fulminant Colitis
por: Williamson, J. M. L., et al.
Publicado: (2011)

Fulminant Guillain-Barré Syndrome with Myocarditis
por: Mishra, Ajay, et al.
Publicado: (2014)

Fulminant myocarditis: Characteristics, treatment, and outcomes
por: Veronese, Giacomo, et al.
Publicado: (2018)

Consideration on pathogen of viral fulminant myocarditis
por: Wei, Xin, et al.
Publicado: (2020)

Fulminant myocarditis and COVID-19. Response
por: Irabien-Ortiz, Ángela, et al.
Publicado: (2020)

Fulminant myocarditis due to COVID-19
por: Irabien-Ortiz, Ángela, et al.
Publicado: (2020)

Fulminant Eosinophilic Myocarditis and VT Storm
por: Hoppens, Kyle R., et al.
Publicado: (2021)

Tozinameran: Fulminant myocarditis: case report
Publicado: (2022)

Anakinra in pediatric acute fulminant myocarditis
por: Maunier, Louise, et al.
Publicado: (2022)

Characteristics of Electrocardiogram Findings in Fulminant Myocarditis
por: Dai, Mei-Yan, et al.
Publicado: (2023)

Impact of mechanical circulatory support and immunomodulation therapy on outcome of patients with fulminant myocarditis: Chinese registry of fulminant myocarditis
por: Zhou, Ning, et al.
Publicado: (2021)

Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination
por: Oka, Akihiro, et al.
Publicado: (2022)

Abatacept/immunosuppressants/ruxolitinib: Various toxicities following off-label use and lack of efficacy: 20 case reports
Publicado: (2022)

Parvovirus B19 Myocarditis of Fulminant Evolution
por: Spartalis, Michael, et al.
Publicado: (2017)

Fulminant myocarditis with myositis of ocular and respiratory muscles
por: Hiraiwa, Hiroaki, et al.
Publicado: (2020)

Glucocorticoid and immunoglobulin to treat viral fulminant myocarditis
por: Wei, Xin, et al.
Publicado: (2020)

SARS-CoV-2 Fulminant Myocarditis
por: Garot, Jérôme, et al.
Publicado: (2020)

Immune-mediated mechanism in coronavirus fulminant myocarditis
por: Wei, Xin, et al.
Publicado: (2020)

Azd-1222: Fulminant myocarditis: case report
Publicado: (2022)

Fulminant Bacterial Myocarditis Presenting as Myocardial Infarction
por: Trpkov, Cvetan, et al.
Publicado: (2020)

Fulminant myocarditis in adults: a narrative review
por: Montero, Santiago, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ks3eq5eku5immhj5n2ll2u3aq4